Gyre Therapeutics, Inc. (GYRE): Revenue
$116.59M
Year ended 2025-12-31
+4.5%
3-year compound annual growth
+41.0%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $116.59M | +10.2% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $105.76M | -6.8% | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | $113.45M | +10.9% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $102.29M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $7.34M | -65.0% | 2022-03-31, From 2021-01-01 |
| 2020-12-31 | $20.95M | n/a | 2022-03-31, From 2020-01-01 |
| No annual figure between 2018-12-31 and 2020-12-31. | |||
| 2018-12-31 | $6.0K | -99.4% | 2020-02-20, From 2018-01-01 |
| 2017-12-31 | $1.02M | n/a | 2019-03-08, From 2017-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $116.59M | +10.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $109.79M | +21.4% |
| Xencor Inc (XNCR) | 2025-12-31 | $125.58M | +13.7% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $107.46M | +66.9% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $106.47M | +350.9% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $105.97M | +38.9% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $128.87M | +0.5% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $94.57M | -31.8% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $146.07M | +0.6% |
Compare GYRE, URGN, XNCR, TBPH side by side · Screen every company in Pharmaceutical Preparations ↗